Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Advanced Breast Cancer × ribociclib × Clear all

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 39 Neoplasm Metastasis 6 Neoplasms 3 Ovarian Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Breast Neoplasms, Male 2 Breast Diseases 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Recurrence 1 Neoplasms by Site 1 Medulloblastoma 1 Lung Neoplasms 1 Locoregional Recurrence 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 HER2 Negative Breast Cancer 1 Glioma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 ER+ HER2- Advanced Breast Cancer 1 Digestive System Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Colorectal Neoplasms 1

Interventions

Fulvestrant 4 trastuzumab deruxtecan 2 elacestrant 2 Vinorelbine 2 talazoparib 1 ribociclib 1 pyrotinib 1 palbociclib 1 olaparib 1 exemestane 1 eribulin 1 disitamab vedotin 1 dalpiciclib 1 apatinib 1 abemaciclib 1 Selective Estrogen Receptor Modulators 1 Ritonavir 1 Radiotherapy 1 RAD1901 1 Letrozole 1 Itraconazole 1 Injections 1 Gonadotropin-Releasing Hormone 1 Everolimus 1 Capecitabine 1 Aromatase Inhibitors 1 Anastrozole 1 Ado-Trastuzumab Emtansine 1 AZD9833 1 AZD5305 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06380751 2026-04-14

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡